Baudax Bio (BXRXQ) 10-Q2023 Q2 Quarterly report

Filed: 16 Aug 23, 8:01am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: adhere, aimed, Allergy, analyst, antigen, appeal, approach, attack, attention, autoimmune, BAR, Biological, biotechnology, blue, BML, BMLA, bond, bondholder, Cancer, carryforward, cease, cell, Chimeric, classification, clearance, cleared, collateral, commitment, comprised, condensed, Conditionally, confidence, counter, create, culture, cure, curtail, daily, deadline, degree, Delaware, demonstrate, deteriorate, disclaimer, discover, dispose, dissolution, divert, divestiture, effector, effort, encoding, engineering, enhancing, enriched, EoFlow, escrow, expand, expenditure, expose, face, Factor, fail, failed, family, firm, Food, forbear, Forbearance, forma, forward, Foundation, fundamental, FVIII, Germantown, half, headcount, healthy, hemophilia, Henry, histocompatibility, HJF, immaterial, immune, immunosuppressive, immunotherapy, inadequate, influence, inhibitory, instrument, intercompany, investee, isolation, iTreg, Jackson, lab, lack, lapse, lose, losing, lot, Maryland, Medicine, merger, Military, misstatement, mitigation, modulating, NCI, NIAID, NIH, noncash, noncompliance, Nonrecurring, nucleic, ODN, orphan, OTCQB, Panel, parity, penny, peptide, platform, pro, proportionate, provisional, quotation, rata, receptor, redemption, remedial, remediate, remediation, reputation, requisite, retroviral, simple, sky, software, stable, stage, stringent, sublicensable, surface, tangible, TCR, Teff, TeraImmune, therapy, TIT, transduced, Treg, TREGable, TREGing, unanimously, Unconverted, undistributed, unmet, unrestricted, unsuccessful, vector, winding

Removed: adequate, assignment, assistance, Assumption, Bifurcation, bring, calculate, call, charge, constant, diversity, efficacy, entirety, freestanding, Hedging, impacting, incorporated, individually, issuer, making, negatively, partial, percentage, presentation, proportion, prospective, reducing, representing, retrospective, Subtopic, suffer, terminated

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

BXRXQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Baudax Bio, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to such officer’s knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 16, 2023

/s/ Gerri A. Henwood

Gerri A. Henwood

President and Chief Executive Officer

(Principal Executive Officer)

/s/ Jillian Dilmore

Jillian Dilmore

Corporate Controller

(Principal Financial and Accounting Officer)